Reply to Frachon: Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension: A Missing Chapter of the Story?

Gérald Simonneau^{1

2

3}, Marc Humbert^{1

2

3}

Affiliations

Comment

Gérald Simonneau et al. Am J Respir Crit Care Med. 2018.

. 2018 May 15;197(10):1364-1365.

doi: 10.1164/rccm.201712-2483LE.

Gérald Simonneau^{1

2

3}, Marc Humbert^{1

2

3}

No abstract available

Comment on

Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension.
Zamanian RT, Hedlin H, Greuenwald P, Wilson DM, Segal JI, Jorden M, Kudelko K, Liu J, Hsi A, Rupp A, Sweatt AJ, Tuder R, Berry GJ, Rabinovitch M, Doyle RL, de Jesus Perez V, Kawut SM. Zamanian RT, et al. Am J Respir Crit Care Med. 2018 Mar 15;197(6):788-800. doi: 10.1164/rccm.201705-0943OC. Am J Respir Crit Care Med. 2018. PMID: 28934596 Free PMC article.
Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension. A New Chapter of the Story.
Simonneau G, Humbert M. Simonneau G, et al. Am J Respir Crit Care Med. 2018 Mar 15;197(6):704-706. doi: 10.1164/rccm.201709-1962ED. Am J Respir Crit Care Med. 2018. PMID: 29043836 No abstract available.
Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension: A Missing Chapter of the Story?
Frachon I. Frachon I. Am J Respir Crit Care Med. 2018 May 15;197(10):1364. doi: 10.1164/rccm.201711-2319LE. Am J Respir Crit Care Med. 2018. PMID: 29272590 No abstract available.